Last reviewed · How we verify
NCT06778278
Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans
NA trial testing Transition Health and Resilience through Valued Experiences (THRiVE) Program in Military Transition in 40 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | RTI International |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 30 July 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transition Health and Resilience through Valued Experiences (THRiVE) Program
Conditions studied
- Military Transition — all drugs for Military Transition →
- Community Reintegration — all drugs for Community Reintegration →
- Mental Health — all drugs for Mental Health →
- Suicidal Ideation — all drugs for Suicidal Ideation →
Sponsor
RTI International — full company profile →
Who can join
18 and older, any sex, with Military Transition or Community Reintegration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to develop and pilot a program designed to improve mental health outcomes and reduce suicide risk during the transition from military to civilian life. It is hypothesized that the Transition Health and Resilience through Valued Experiences (THRiVE) program, to be developed as part of this study, will meet participant recruitment, retention, and satisfaction benchmarks (primary outcomes) and show positive preliminary effects on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes (secondary outcomes). The specific aims of this study are to: 1. Develop a small-group, peer-led, cross-cutting prevention program for newly separated veterans (NSVs) called THRiVE and 2. Evaluate the feasibility, acceptability, and preliminary effects of the THRiVE program on mental health symptoms, risk factors for suicidal ideation, and psychosocial functioning outcomes. Up to 40 NSVs participating in this Stage 1 pilot study will complete validated self-report measures at baseline, immediately after completing the THRiVE program (post-THRiVE), and 3 months after completing the THRiVE program (follow-up). The duration of a participant's time in the study is anticipated to be 5 months.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bringing veteran mental health promotion and suicide prevention efforts upstream: The THRiVE study protocol.
Blakey SM, Vandermaas-Peeler JR, Counts J, Croxford J, et al · · 2025 · PMID 41052716 · DOI 10.1016/j.cct.2025.108100
Verify or expand the search:
- PubMed search for NCT06778278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other RTI International trials
Trials by the same sponsor.
- NCT07226401 — Virtual Village for Young Parents · NA · recruiting
- NCT06927661 — ENSAND 2.0 Evaluation in Nigeria · NA · recruiting
- NCT06927674 — DELIVER Evaluation in Nigeria · NA · recruiting
- NCT05971888 — Better Dairy for All Evaluation in Ethiopia · NA · withdrawn
- NCT06249386 — Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06778278 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RTI International
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing